Gd-DOTA | CAS# 92923-44-9 | MRI contrast agent

MedKoo Cat#: 413907 | Name: Gd-DOTA

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Gd-DOTA is a potential MRI contrast agent

Chemical Structure

Gd-DOTA

CAS#92923-44-9

Theoretical Analysis

MedKoo Cat#: 413907

Name: Gd-DOTA

CAS#: 92923-44-9

Chemical Formula: C16H24GdN4NaO8

Exact Mass: 0.0000

Molecular Weight: 580.63

Elemental Analysis: C, 33.10; H, 4.17; Gd, 27.08; N, 9.65; Na, 3.96; O, 22.04

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Gd-DOTA; Gadolinium dota; Dotarem; Gadoterate sodium

IUPAC/Chemical Name

Gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate

InChi Key

DFTYBKPBYWCVAV-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H28N4O8.Gd.Na/c21-13(22)9-17-1-2-18(10-14(23)24)5-6-20(12-16(27)28)8-7-19(4-3-17)11-15(25)26;;/h1-12H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28);;/q;-1;+1

SMILES Code

O=C1CN23CCN45CCN67CCN8(CC([O-][Gd+3]3468([O-]C(C5)=O)([O-]1)[O-]C(C7)=O)=O)CC2.[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 580.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gulino P, Bianchi A, Diciotti S, Scionti A, Sali L, Papadopulos P, Mascalchi M. The switch from Gd-DTPA to Gd-DOTA is not associated with decrease of the T1 signal intensity of the pallidus and dentate in a pediatric population. Acta Radiol. 2021 Mar;62(3):368-376. doi: 10.1177/0284185120927920. Epub 2020 Jun 12. PMID: 32529894. 2: Forero Ramirez LM, Gobin E, Aid-Launais R, Journe C, Moraes FC, Picton L, Le Cerf D, Letourneur D, Chauvierre C, Chaubet F. Gd(DOTA)-grafted submicronic polysaccharide-based particles functionalized with fucoidan as potential MR contrast agent able to target human activated platelets. Carbohydr Polym. 2020 Oct 1;245:116457. doi: 10.1016/j.carbpol.2020.116457. Epub 2020 May 25. PMID: 32718599. 3: Wybranski C, Siedek F, Damm R, Gazis A, Wenzel O, Haneder S, Persigehl T, Steinhauser S, Pech M, Fischbach F, Fischbach K. Respiratory motion artefacts in Gd-EOB-DTPA (Primovist/Eovist) and Gd-DOTA (Dotarem)-enhanced dynamic phase liver MRI after intensified and standard pre-scan patient preparation: A bi- institutional analysis. PLoS One. 2020 Mar 20;15(3):e0230024. doi: 10.1371/journal.pone.0230024. PMID: 32196535; PMCID: PMC7083299. 4: Wang H, Sebrié C, Judé S, Maurin A, Rétif S, Le Mée M, Julea F, Dubuisson RM, Willoquet G, Bouazizi K, Darrasse L, Guillot G, Maître X, de Rochefort L. Quantitative Gd-DOTA-based aerosol deposition mapping in the lungs of asthmatic rats using 3D UTE-MRI. NMR Biomed. 2018 Dec;31(12):e4013. doi: 10.1002/nbm.4013. Epub 2018 Oct 11. PMID: 30307075. 5: Lee H, Mortensen K, Sanggaard S, Koch P, Brunner H, Quistorff B, Nedergaard M, Benveniste H. Quantitative Gd-DOTA uptake from cerebrospinal fluid into rat brain using 3D VFA-SPGR at 9.4T. Magn Reson Med. 2018 Mar;79(3):1568-1578. doi: 10.1002/mrm.26779. Epub 2017 Jun 19. PMID: 28627037; PMCID: PMC5736474. 6: Demine S, Balhuizen A, Debaille V, Joosten L, Fereau M, Chilla SNM, Millard I, Scharfmann R, Egrise D, Goldman S, Marchetti P, Gotthardt M, Laurent S, Burtea C, Eizirik DL. Imaging of Human Insulin Secreting Cells with Gd-DOTA-P88, a Paramagnetic Contrast Agent Targeting the Beta Cell Biomarker FXYD2γa. Molecules. 2018 Aug 21;23(9):2100. doi: 10.3390/molecules23092100. PMID: 30134599; PMCID: PMC6225257. 7: Zhang P, Zhang Y, Li B, Zhang H, Lin H, Deng Z, Tan B. Cell-assembled nanoclusters of MSC-targeting Gd-DOTA-peptide as a T2 contrast agent for MRI cell tracking. J Pept Sci. 2018 Jun;24(4-5):e3077. doi: 10.1002/psc.3077. Epub 2018 Mar 27. PMID: 29582508. 8: Colosimo C, Knopp MV, Barreau X, Gérardin E, Kirchin MA, Guézénoc F, Lodemann KP. A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology. 2004 Aug;46(8):655-65. doi: 10.1007/s00234-003-1128-4. Epub 2004 Jun 15. PMID: 15205859. 9: Bousquet JC, Saini S, Stark DD, Hahn PF, Nigam M, Wittenberg J, Ferrucci JT Jr. Gd-DOTA: characterization of a new paramagnetic complex. Radiology. 1988 Mar;166(3):693-8. doi: 10.1148/radiology.166.3.3340763. PMID: 3340763. 10: Mortensen KN, Sanggaard S, Mestre H, Lee H, Kostrikov S, Xavier ALR, Gjedde A, Benveniste H, Nedergaard M. Impaired Glymphatic Transport in Spontaneously Hypertensive Rats. J Neurosci. 2019 Aug 7;39(32):6365-6377. doi: 10.1523/JNEUROSCI.1974-18.2019. Epub 2019 Jun 17. PMID: 31209176; PMCID: PMC6687896.